share_log
Reuters ·  Apr 25 08:03
Roivant and Kinevant Sciences Complete Enrollment in Resolve-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment